Emergent BioSolutions (EBS) Tops Q1 EPS by 41c; Guides Q2 Revs Lower
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.23 +6.13%
Revenue Growth %: -45.6%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: -45.6%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $1.53, $0.41 better than the analyst estimate of $1.12. Revenue for the quarter came in at $343 million versus the consensus estimate of $358.47 million.
GUIDANCE:
Emergent BioSolutions sees Q2 2021 revenue of $370-430 million, versus the consensus of $502.3 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance
- Skillsoft (SKIL) Tops Q2 EPS by 14c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
